PET/CT in Diagnosis of Mixed Hepatocholangiocellular Cancer. Case report
https://doi.org/10.37174/2587-7593-2019-2-2-92-100
Abstract
Purpose: To estimate the diagnosis value of PET/CT with 18F-choline and 18F-FDG in case of mixed hepatocellular (HCC) and cholangiocellular cancer (CCC).
Material and methods: PET/CT with 18F-choline and 18F-FDG was performed on 56 years old patient with diagnosed liver cancer. Contrast-enhanced CT and MRI, histological and immunohistochemical studies of postoperative material were also performed.
Results: Difference of the accumulation of 18F-choline and 18F-FDG in some areas of mixed hepatocellular and cholangiocellular cancer was detected: in the field of CCC and in the field of poor-differentiated HCC.
Conclusions: 18F-choline has a low diagnostic value in the detection of CCC and poor differentiated HCC, in contrast to 18F-FDG.
About the Authors
P. E. Tulin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Moscow.
Russian Federation
Moscow.
M. B. Dolgushin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Moscow.
Russian Federation
Moscow.
A. A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Moscow.
B. M. Medvedeva
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. Патютко Ю.И., Сагайдак И.В., Чучуев Е.С. и соавт. Гепатоцеллюлярный рак печени // Бюлл. медицинских интернет-конференций. 2011. Т.1, С. 35–61.
2. Чиссов В.И. Онкология. – М.: ГЭОТАР. 2007. 605 с.
3. Суконко О.Г. Гепатоцеллюлярный рак. Алгоритм диагностики и лечения злокачественных новообразований. – Минск. 2012. 105 с.
4. Bosh F.X., Ribes J., Borras J. Epidemiology of primary liver cancer // Semin. Liver Dis. 1999. Vol. 19. P. 271–285.
5. Beasley R.P., Hwang L.Y. Overview on the epidemiology of hepatocellular carcinoma // Viral Hepatitis and Liver Disease. 1991. P. 532–535.
6. Huo T.I., Lee S.D., Wu J.C. For hepatocellular carcinoma: look for a perfect classification system // J. Hepatol. 2004. Vol. 40. № 6. P. 1041–1042.
7. Barazani Y., Hiatt J.R., Tong M.J. et al. Chronic viral hepatitis and hepatocellular carcinoma // World J. Surg. 2007. Vol. 31. P. 1245–1250.
8. Jeong S., Aviata H., Katamura Y. et al. Low-dose intermittent interferon – alpha-therapy for HCV-related liver cirrosis after curative treatment of hepatocellular carcinoma // World J. Gastroenterology. 2007. Vol. 113. P. 5188–5195.
9. Зогот С.Р., Акберов Р.Ф., Зыятдинов К.Ш., Варшавский Ю.В. Гепатоцеллюлярный рак (эпидемиология, лучевая диагностика, современные аспекты лечения) // Практическая медицина. 2013. № 2(67). С. 21–29.
10. Майстренко Н.А., Шейко С.Б., Алентьев А.В. Азимов Ф.Х. Холангиоцеллюлярный рак (особенности диагностики и лечения) // Практическая онкология. 2008. Т.9. № 4. С. 229–236.
11. Caturelli E., Pompili M., Bartolucci F. Hemangioma-like lesions in chronic liver disease: diagnostic evaluation in patients // Radiology. 2001. Vol. 220. № 2. P. 337–342.
12. Matsui O., Kadoya M., Kameyama T. et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply // Radiology. 1991. Vol. 178. № 2. Р. 493–497.
13. Xu H.X., Liu G.J., Lu M.D. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent // J. Clin. Ultrasound. 2006. Vol. 34. № 6. P. 261–272.
14. Lencioni R., Piscaglia F., Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma// J. Hepatol. 2008. Vol. 48. № 5. P. 848–857.
15. Tiferes D., D’ippolito G. Liver neoplasms: imaging characterization // Radiol. Bras. 2008. Vol. 41. № 22. P. 119–127.
16. Ward J., Robinson P.j. How to detect hepatocellular carcinoma in cirrhosis // Eur. Radiol. 2002. Vol. 12. № 9. P. 2258–2273.
17. Prokop M. Spiral and multislice computed tomography of the body. – Thieme. 2003. 430 pp.
18. Медведева Б.М., Лукьянченко А.Б. Возможности МРТ в диагностике гепатоцеллюлярного рака у пациентов с циррозом печени // REJR. 2013. Т. 3. № 2. С 63–71.
19. Jeong Y., Yim N.Y., Kang H.K. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules // AJR. 2005. Vol. 185. № 4. P. 1024–1032.
20. Lee M.H., Kim S.H., Park M.J. Gadoxetic acid–enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease // AJR. 2011. Vol. 197. № 5. P. 868–875.
21. Nasu K., Kuroki Y., Tsukamoto T., Nakajima, H. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade // AJR. 2009. Vol. 193. № 2. P. 438–444.
22. Ferucci J. MRI of the liver // AJR. 1985. Vol. 147. № 2. P. 1103–1116.
23. Yamamoto Y., Nishiyama Y., Kameyama R. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET // J. Nucl. Med. 2008. Vol. 49. № 8. P. 1245–1248.
24. Hwang K. H., Choi D.-J., Lee S. Y. et al. Evaluation of patients with hepatocellular carcinomas using [11C]-acetate and [18F]-FDG PET/CT: a preliminary study // Radiat. Isotop. 2009. Vol. 67. № 7–8. P. 1195–1198.
25. Trojan J., Schröder O., Raedle J. et al. [18F]-FDG Positron emission tomography for imaging of hepatocellular carcinoma // Amer. J. Gastroenterol. 1999. Vol. 94. № 11. P. 3314–3319.
26. Talbot J., Gutman F., Fartoux L. et al. PET/CT in patients with hepatocellular carcinoma using [18F]-fluorocholine: preliminary comparison with [18F]-FDG PET/CT // Eur. J. Nucl. Med Mol. Imaging. 2006. Vol. 33. № 11. P. 1285–1289.
27. Esschert J.W., Bieze M., Beuers U. H. et al. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-Fluorocholine PET/CT // Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38. № 3. P. 436–440.
28. Lee J., Paeng J., Kang K. W. et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma // J. Nucl. Med. 2009. Vol. 50.
29. Kuang Y., Salem N., Tian H. et al. Imaging lipid synthesis in hepatocellular carcinoma with [methyl–11C]-choline: correlation with in vivo metabolic studies // J. Nucl. Med. 2011. Vol. 52. № 1. P. 98–106.
30. Moon C.M., Bang S., Chung J.B. et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas // J. Gastroenterol. Hepatol. 2008. Vol. 23. № 5. P. 759–765.
31. Kluge R., Schmidt F., Caca K. et al. Positron emission tomography with [18F]-fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer // Hepatology. 2001. Vol. 33. № 5. P. 1029–1035.
32. Тулин П.Е., Долгушин М.Б., Оджарова А.А. и соавт. КТ-перфузия и ПЭТ с 18F-ФДГ и 18F-ФХ в комплексной диагностике гепатоцеллюлярного рака // Лучевая диагностика и терапия. 2015. Т. 6. № 3. С. 59–69.
Review
For citations:
Tulin P.E., Dolgushin M.B., Odzharova A.A., Medvedeva B.M. PET/CT in Diagnosis of Mixed Hepatocholangiocellular Cancer. Case report. Journal of oncology: diagnostic radiology and radiotherapy. 2019;2(2):92-100. (In Russ.) https://doi.org/10.37174/2587-7593-2019-2-2-92-100
Views:
437
Email this article 